Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970601 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL20073946 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL20065142 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL25831240 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL20074021 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL20065133 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL25831193 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL29970944 | 1.00 | KDM1A (0.49) | KDM1AKCNH2KDM1BSLC9A1CA1 | |
| SCHEMBL6901544 | 0.90 | SLC9A1 (0.56) | SLC9A1CA1CA2CA9CA12 | |
| SCHEMBL18272445 | 0.88 | ALDH1A1 (0.47) | KDM1ASLC9A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| CN-116425754-A | Aromatic heterobicyclic compounds and antiviral uses thereof | 苏州爱科百发生物医药技术有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-3746444-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-09 | — | — | EP | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
| CN-111670189-A | Cycloalkyl-substituted pyrazolopyrimidines having activity on RSV | 爱尔兰詹森科学公司 | 2020-09-15 | — | — | CN | disclosed |
| WO-2019149734-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-08 | — | — | WO | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2009154780-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | ACE, ACE2, PTBP1 | KDM1A 3168/4885KCNH2 1886/4885KDM1B 3491/4885 |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | S1PR1, S1PR5, S1PR2 | KDM1A 2014/4885KCNH2 1285/4885KDM1B 2269/4885 |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | KDM1A 3024/4885KCNH2 1699/4885KDM1B 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.